Preparation, Assay, and Application of Chlorinase SalL for the Chemoenzymatic Synthesis of S-Adenosyl-L-Methionine and Analogs

Tony D. Davis*, Sylvia Kunakom[†], Michael D. Burkart*,[1], Alessandra S. Eustaquio[†],[1]
*University of California San Diego, San Diego, CA, United States
[†]University of Illinois at Chicago, College of Pharmacy, and Center for Biomolecular Sciences, Chicago, IL, United States
[1]Corresponding authors: e-mail address: mburkart@ucsd.edu; ase@uic.edu

Contents

Abstract

S-adenosyl-L-methionine (SAM) is universal in biology, serving as the second most common cofactor in a variety of enzymatic reactions. One of the main roles of SAM is the methylation of nucleic acids, proteins, and metabolites. Methylation often imparts

regulatory control to DNA and proteins, and leads to an increase in the activity of specialized metabolites such as those developed as pharmaceuticals. There has been increased interest in using SAM analogs in methyltransferase-catalyzed modification of biomolecules. However, SAM and its analogs are expensive and unstable, degrading rapidly under physiological conditions. Thus, the availability of methods to prepare SAM in situ is desirable. In addition, synthetic methods to generate SAM analogs suffer from low yields and poor diastereoselectivity. The chlorinase SalL from the marine bacterium *Salinispora tropica* catalyzes the reversible, nucleophilic attack of chloride at the C5′ ribosyl carbon of SAM leading to the formation of 5′-chloro-5′-deoxyadenosine (ClDA) with concomitant displacement of L-methionine. It has been demonstrated that the in vitro equilibrium of the SalL-catalyzed reaction favors the synthesis of SAM. In this chapter, we describe methods for the preparation of SalL, and the chemoenzymatic synthesis of SAM and SAM analogs from ClDA and L-methionine congeners using SalL. In addition, we describe procedures for the in situ chemoenzymatic synthesis of SAM coupled to DNA, peptide, and metabolite methylation, and to the incorporation of isotopes into alkylated products.

1. INTRODUCTION

S-adenosyl-L-methionine (SAM or AdoMet) is ubiquitous in nature and the second most utilized enzyme substrate after adenosine triphosphate (ATP). SAM is not only a source of methyl groups to methylate a variety of substrates, including nucleic acid, proteins, and small molecules (Cantoni, 1975; Thomsen, Vogensen, Buchardt, Burkart, & Clausen, 2013), but also a source of methylene, amino, ribosyl, and aminopropyl groups, in addition to 5′-deoxyadenosyl radicals (Fontecave, Atta, & Mulliez, 2004). Remarkably, SAM has also recently been shown to serve as a cofactor in coordinating pericyclic reactions via electrostatic catalysis (Ohashi et al., 2017). Another role for SAM is to serve as a substrate in reactions catalyzed by SAM-dependent halogenases of the 5′-halo-5′-deoxyadenosine (XDA) synthase class (Agarwal et al., 2017; Dong et al., 2004; Eustáquio, Pojer, Noel, & Moore, 2008).

Halogenated compounds are pervasive across all domains of life. Over 5000 organohalogens are known. Organochlorines and organobromines are the most abundant with >2000 known examples of each, whereas organoiodines are more scarce (<200) and organofluorines are very rare with only five rigorously identified compounds (Chan & O'Hagan, 2012; Gribble, 2012; Wang, Zhou, Fredimoses, Liao, & Liu, 2014). Halogenating enzymes employ various mechanistic strategies depending on the properties

of the halogen atom and the reactivity of the organic substrate. Most halogenases activate chloride, bromide, and iodide via oxidation by utilizing cofactors such as heme–iron, vanadium, flavin, and Fe(II)/α–ketoglutarate (Agarwal et al., 2017). For fluoride, on the other hand, which evades oxidation due to its extreme electronegativity, an orthogonal strategy has been described that uses SAM as a cosubstrate in an S_N2-type, nucleophilic substitution reaction (Fig. 1). The only fluorinase described thus far (FlA) catalyzes the first committed step in the biosynthesis of fluoroacetate and fluorothreonine in the soil bacterium *Streptomyces cattleya* in which fluoride attacks the C5′ electrophilic carbon of SAM, displacing L-methionine and generating 5′-fluoro-5′-deoxyadenosine (FDA) (Dong et al., 2004). FlA was later identified in other bacteria in addition to *S. cattleya* (Deng et al., 2014; Huang et al., 2014).

Four years after the structural characterization of the fluorinase, the chlorinase SalL was reported from the marine bacterium *Salinispora tropica* (Eustáquio et al., 2008). SalL is analogous to fluorinase and the only other structurally characterized SAM–dependent halogenase of the XDA synthase class (Fig. 1). SalL catalyzes the first committed step in the biosynthesis of proteasome inhibitor salinosporamide A (Eustáquio et al., 2009, 2008; Feling et al., 2003). Both FlA and SalL can also catalyze the reverse reaction, i.e., synthesis of SAM from XDA. For FlA, the in vitro equilibrium

Fig. 1 Reaction catalyzed by SAM-dependent halogenases. Fluorinase FlA from soil bacterium *Streptomyces cattleya* (Dong et al., 2004) and chlorinase SalL from marine bacterium *Salinispora tropica* (Eustáquio et al., 2008) catalyze reversible S_N2-type, nucleophilic substitution reactions in which the halide attacks the C5′ ribosyl carbon of SAM, generating 5′-halo-5′-deoxyadenosine (XDA) and releasing L-methionine. FlA and SalL catalyze the first committed step in the biosynthesis of fluorometabolites and salinosporamide A, respectively.

lies in favor of FDA by a factor of three (Dong et al., 2004). That the forward reaction is favored by FlA is unsurprising given that the C–F bond is the strongest bond in organic chemistry. For chlorinase SalL, on the other hand, synthesis of SAM from 5′-chloro-5′-deoxyadenosine (ClDA) and L-methionine (L-met) is favored, with the relative enzyme efficiency (k_{cat}/K_m) for the reverse reaction (SAM synthesis) being several orders of magnitude higher than the forward halogenation reaction (Eustáquio et al., 2008). The fluorinase was also reported to favor the reverse reaction in vitro when using chloride as the halide (Deng et al., 2006).

As a versatile methyl donor to biomolecules, there has been considerable interest in exploring the synthesis of SAM analogs of chemical and biological utility. For instance, nonnatural SAM analogs could be used to modify cellular targets such as DNA, RNA, proteins, and metabolites. Moreover, SAM itself is an expensive and unstable cofactor, degrading rapidly under physiological or alkaline conditions. Thus, the availability of methods to prepare SAM in situ is desirable.

Traditionally, SAM analogs have been chemically synthesized from S-adenosyl-L-homocysteine. However, this synthesis suffers from low yields and lack of diastereoselectivity (Dalhoff, Lukinavicius, Klimasauskas, & Weinhold, 2006a, 2006b). Furthermore, SAM synthesis is challenging due to its inherent lability and tendency to racemize (Hoffman, 1986). Chemoenzymatic synthesis using chlorinase SalL and ClDA offers an alternative to chemical synthesis. In addition to being stable and commercially available, ClDA can also be synthesized economically from adenosine and $SOCl_2$ (Sinhababu, Bartel, Pochopin, & Borchardt, 1985). Chemoenzymatic synthesis of SAM and analogs in situ could also be coupled with downstream applications such as methylation or alkylation by methyltransferases. This strategy can also be used for the facile incorporation of isotopes into alkylated products.

We have demonstrated the use of SalL for the diastereoselective synthesis of SAM and SAM congeners from ClDA and L-met analogs (see Section 3). We have also coupled the SalL–catalyzed production of SAM with DNA and with metabolite methylation (Lipson et al., 2013). Importantly, we have demonstrated that in situ generated SAM analogs were recognized by rat protein arginine methyltransferase 1 (rPRMT1) which alkylated its peptide substrate (Thomsen et al., 2013).

In this chapter, we describe procedures for the preparation and assay of SalL, the SalL-mediated chemoenzymatic synthesis of SAM analogs from

ClDA and L-met congeners, and the in situ chemoenzymatic synthesis of SAM coupled to DNA, peptide, and metabolite methylation, and to the incorporation of isotopes into alkylated products.

2. PREPARATION AND ASSAY OF CHLORINASE SalL

2.1 Purification of Recombinant SalL From *Escherichia coli*

Recombinant SalL containing a N-terminal His_8 tag was obtained by gene expression in and protein purification from *E. coli* BL21(DE3) (Eustáquio et al., 2008).

2.1.1 Cloning of the salL Gene Into an Expression Vector

The *salL* gene can be amplified by PCR using total genomic DNA isolated from *S. tropica* CNB-440 as a template and appropriate primers. The following are suggested primers that were used to clone *salL* into pHIS8 (Jez, Ferrer, Bowman, Dixon, & Noel, 2000) by restriction/ligation, yielding plasmid pAEM7 (Eustáquio et al., 2008):

for: 5′-CGTGGTTC<u>CCATGG</u>*CATG*CAGCACAATCTCATTGC-3′ (*Nco*I site underlined)

rev: 5′-GCTCGAATT<u>CAAGCTT</u>*GTCAGCTACCCGAGCACCG*-3′ (*Hin*dIII site underlined)

The primers were designed to ensure that the ATG (Met start codon, bold) was in-frame with the His_8 tag. The priming sites are in italics. Bases upstream of the restriction sites are random sequences to facilitate cutting of the PCR product with the respective restriction enzyme. *salL* was amplified by PCR using the Expand High Fidelity PCR system (Roche) following the manufacturer's instructions and using 5% DMSO (v/v) and annealing temperature of 58°C. Alternative, proofreading DNA polymerases include Q5® High Fidelity polymerase and Phusion® High Fidelity polymerase (New England Biolabs). The expected size of the PCR product when using the primers above is 888 bp. Alternatively, synthetic DNA can be ordered from GenScript. The accession code for the *salL* gene (Strop_1026) of *S. tropica* CNB-440 is NC_009380.1 (position 1,162,700 to 1,163,551, complement). If using the primers above, digest the PCR product with *Nco*I and *Hin*dIII and ligate it into the same sites of pHIS8 to yield the pHIS8-*salL* expression vector (pAEM7). While the PCR product can be digested and cloned directly into pHIS8, we subcloned the PCR product into the pGEM-T Easy vector (Promega) by following the manufacturer's

instructions. The insert of the obtained plasmid (pAEM5) was sequenced and confirmed to contain no mistakes. Following digestion of pAEM5 with *Hin*dIII, *Nco*I, and *Dra*I (DraI cuts only the vector backbone), and iso-propanol precipitation, the *Hin*dIII–*Nco*I *salL* fragment (868 bp) was cloned into the same sites of pHIS8. pHIS8 contains an N–terminal, 8 × His tag that will facilitate protein purification. Note that the pAEM7 *salL* expression plasmid used here contains native DNA from *S. tropica* rather than DNA which is codon-optimized for expression in *E. coli*.

2.1.2 Expression of salL in E. coli BL21(DE3) and Purification of Recombinant SalL Enzyme

2.1.2.1 Materials
- Competent *E. coli* BL–21 (DE3) cells (Novagen)
- *salL* expression vector (pAEM7)
- Luria–Bertani (LB) agar (Becton Dickinson)
- LB broth (Becton Dickinson)
- Terrific broth (TB) medium (Becton Dickinson)
- Ni^{2+}-NTA resin (Qiagen)
- Lysis buffer: 50 mM sodium phosphate buffer (pH 8.0), 500 mM NaCl, 20 mM imidazole (pH 8.0), 20 mM β–mercaptoethanol, 10% (v/v) glycerol, and 1% (v/v) Tween-20, and 1 mg/mL lysozyme
- Wash buffer: 50 mM sodium phosphate buffer (pH 8.0), 500 mM NaCl, 20 mM imidazole (pH 8.0), 20 mM β–mercaptoethanol, and 10% (v/v) glycerol
- Elution buffer: 50 mM sodium phosphate buffer (pH 8.0), 500 mM NaCl, 250 mM imidazole (pH 8.0), 20 mM β–mercaptoethanol, and 10% (v/v) glycerol
- Storage buffer: 50 mM sodium phosphate buffer (pH 7.9), 20% glycerol
- Disposable polypropylene column (from Qiagen)
- Disposable PD-10 desalting columns (Sephadex G-25, GE Healthcare)
- SDS-PAGE (10% Bis-Tris NuPAGE gel with MOPS running buffer, ThermoFisher)

2.1.2.2 Procedure
1. Competent *E. coli* BL–21 (DE3) cells are commercially available (e.g., Novagen, cat. No. 69450-3). Follow the manufacturer's instructions to introduce the *salL*-containing expression vector into *E. coli* BL–21 (DE3) by chemical transformation. Plate the transformation reaction

on LB agar containing 50 mg/L kanamycin (pHIS8 contains a kanamycin–resistance gene) and incubate the plates overnight at 37°C.

2. Inoculate a single colony onto 50 mL LB containing 50 mg/L kanamycin (use a 250-mL flask) and incubate the flask overnight at 37°C, 200 rpm.

3. Prepare cryo stocks for long-term storage by mixing the *E. coli* BL21 (DE3) culture containing the *salL* plasmid 1:1 with sterile glycerol 40%, giving a final glycerol concentration of 20%. Store cryo stocks at −80°C.

4. Use the overnight LB culture to inoculate 1 L of TB media containing 50 mg/L kanamycin so that the starting $A_{600} = 0.1$ (10–20 mL of the overnight *E. coli* seed culture are expected to be necessary). Incubate the flask at 25°C, 225 rpm until $A_{600} = 0.8$. Once an A_{600} of 0.8 is reached, induce cells with 0.25 mM IPTG (final concentration) and incubate overnight at 20°C, 225 rpm. A 2.8-L Fernbach flask is recommended for cultivation of 1 L cultures.

5. Harvest cells by centrifugation (e.g., 15 min at $5000 \times g$) and resuspend the cell pellet in ~20 mL of cold lysis buffer. Incubate on ice for 30 min.

6. *Note*: take care to keep the preparation cold by cooling centrifuges, buffers, and keeping the sample on ice.

7. Lyse cells by sonication on ice (e.g., 2 s on, 2 s off for 3 min total). Alternatively, a French press can be used for cell lysis.

8. Centrifuge the lysate at high speed ($>10,000 \times g$) for 30 min at 4°C.

9. The clear lysate is then purified using Ni^{2+}-NTA resin (Qiagen) and a modified batch purification method as briefly described below (refer to the manufacturer's instructions "The QIAexpressionist" for more details).

10. Transfer the clear lysate to a clean, autoclaved beaker on ice, and add 5 mL Ni^{2+}-NTA to the clear lysate. Mix gently using a magnetic stirrer for 1 h. Alternatively, use a rotary shaker for mixing the sample contained in a conical tube.

11. If using a beaker for mixing, transfer the lysate/Ni–NTA suspension to a conical tube and centrifuge at $3000 \times g$ for 5 min at 4°C to collect the Ni–NTA resin.

12. Discard the supernatant and wash the resin twice with 25 mL wash buffer each as following. Add 25 mL wash buffer to the Ni–NTA pellet, resuspend gently, and centrifuge at $3000 \times g$ for 5 min at 4°C. Discard supernatant and repeat.

13. After the last wash, resuspend the Ni–NTA pellet in ~5 mL wash buffer and transfer the resin to an empty polypropylene column with the bottom outlet capped. Remove bottom cap and discard flow–through. Wash once with 25 mL cold wash buffer. Discard flow–through.
14. Elute the His$_8$-tagged SalL with 2× 5 mL elution buffer.
15. Assess the quality of the protein preparation using SDS-PAGE (e.g., 10% Bis–Tris NuPAGE gel with MOPS running buffer, Thermo-Fisher). The expected size of the His$_8$-tagged protein is 32.4 kDa (Fig. 2).
16. The expected yield is >60 mg recombinant, soluble SalL per liter of culture. Protein yield can be calculated using the Bradford assay (Bradford, 1976).
17. Desalting can be performed using PD-10 columns (Sephadex G-25): cut the bottom tip off the column and let the storage liquid flow (discard); equilibrate the column with 25 mL storage buffer; load sample in a total volume of 2.5 mL per PD-10 column; discard the flow–through; elute with 3.5 mL storage buffer. Alternatively, dialysis can be used for desalting.

2.2 SalL Activity Assay

The reaction catalyzed by chlorinase SalL is reversible. Chloride, bromide, and iodide are accepted as the halide cosubstrates in the reaction with SAM (forward reaction) to yield XDA. Kinetic studies demonstrated that the


Fig. 2 SDS-PAGE analysis of purified, recombinant SalL. 10% Bis-Tris NuPAGE gel with MOPS running buffer (ThermoFisher). L, Fisherbrand EZ-Run protein marker; (1) soluble protein before induction; (2) soluble protein after induction; and (3) His$_8$-SalL purified by Ni-NTA affinity chromatography.

reverse reaction (formation of SAM from XDA and L–met) is favored in vitro, with the relative enzyme efficiency (k_{cat}/K_m) of the reverse reaction being orders of magnitude higher than the forward reaction (Eustáquio et al., 2008). The activity of recombinant SalL can be investigated by a HPLC-based method as described below.

2.2.1 Reagents
- S-adenosyl–L–methionine (Sigma–Aldrich)
- KCl (analytical grade)
- L–Methionine (Sigma–Aldrich)
- 5′–Chloro–5′–deoxyadenosine (Sigma–Aldrich)
- 50 mM sodium phosphate buffer pH 7.9
- Recombinant SalL (Section 2.1)

2.2.2 Instrumentation and Solvents
- Agilent HPLC 1200
- C18 column (250 × 4.60 mm, 5 µm particle size)
- Mobile phase A: 95% 50 mM KH_2PO_4; 5% acetonitrile
- Mobile phase B: 80% 50 mM KH_2PO_4; 20% acetonitrile
- *Note*: 50 mM KH_2PO_4 gives pH ~4.5; there is no need to adjust the pH.

2.2.3 Procedure
1. In order to test if your SalL preparation is active, set up two different reactions by incubating SalL (400 nM) with
   (i) SAM (0.5 mM) and KCl (400 mM)
   (ii) L–Methionine (10 mM) and ClDA (0.5 mM)
   in 50 mM sodium phosphate buffer (pH 7.9) at 37°C for 1 h. In addition, set up following controls: reactions with inactivated enzyme (the enzyme is first boiled for 5 min and then, the reagents are added) and boiled enzyme only (the enzyme is boiled for 5 min in buffer).
2. Boil the reaction mixture for 2 min at 95°C and centrifuge for 30 min, $10,000 × g$ to remove precipitated protein. 10 µL of clear supernatant is then analyzed by HPLC using a C18 column (250 × 4.60 mm, 5 µm particle size) and 1 mL/min flow rate. After equilibrating the system for at least 15 min using 100% mobile phase A, run following gradient: 100% A for 1 min, 0%–100% B for 29 min, 100%–0% B over 5 min, 100% A for 5 min. Inject also SAM and ClDA standards for comparison.

The retention times obtained under the conditions described were 16.4 min (ClDA) and 18.1 min (SAM).

3. *Notes*:
    - SAM is unstable and SAM solutions should be freshly prepared.
    - Recombinant SalL purified from *E. coli* copurifies with adenosine and ClDA. Thus, the boiled enzyme negative control may have a small peak corresponding to ClDA.

3. CHEMOENZYMATIC SYNTHESIS OF SAM ANALOGS

3.1 Overview of Chemoenzymatic Methods to Prepare SAM and SAM Analogs

SAM is biosynthesized by methionine adenosyltransferases (MAT) from methionine and ATP (Cantoni, 1975; Fig. 3). SAM is an essential cofactor for SAM–dependent methyltransferases to methylate various substrates including nucleic acids, proteins, lipids, and small molecules (Bauerle, Schwalm, & Booker, 2015; Lin, 2011; Martin & McMillan, 2002; Struck, Thompson, Wong, & Micklefield, 2012). While transmethylation produces small and modest chemical changes, these drastically affect molecular recognition of substrates by cellular targets to control processes such as


Fig. 3 Biosynthesis, utilization, and chemoenzymatic synthesis of *S*-adenosyl-L-methionine (SAM) analogs. (A) Biosynthesis of SAM in vivo is catalyzed by L-methionine-adenosyltransferases (MAT). Subsequently, nucleic acid, protein, or small molecule substrates are methylated by SAM-dependent methyltransferases (MT). *SAH*, *S*-adenosyl-L-homocysteine. (B) Chemoenzymatic synthesis of SAM analogs in vitro using chlorinase SalL from *Salinispora tropica*. *ClDA*, 5′-chloro-5′-deoxyadenosine.

epigenetic regulation of protein expression, neurotransmission, and natural products biosynthesis. The prevalence of SAM in cellular processes has inspired the development of analogs as chemical reporters for nucleic acid (Dalhoff et al., 2006a, 2006b; Lukinavicius et al., 2007; Motorin et al., 2011; Vranken et al., 2016), protein (Guo et al., 2014; Islam et al., 2012, 2013; Islam, Zheng, Yu, Deng, & Luo, 2011; Peters et al., 2010; Wang et al., 2013; Wang & Luo, 2013; Wang, Zheng, Yu, Deng, & Luo, 2011), small molecule (Lee et al., 2010; Singh et al., 2014; Stecher et al., 2009; Thomsen et al., 2013; Zhang, Weller, Thorson, & Rajski, 2006), and natural products methyltransferases (Winter et al., 2013; Zhang et al., 2006).

The preparation of SAM and its analogs is especially challenging due to inherent lability, tendency to racemize under experimental conditions, and rapid degradation at physiological pH (Hoffman, 1986). Chemical synthesis of SAM and SAM derivatives involves nucleophilic substitution between *S*-adenosyl-L-homocysteine (SAH or AdoCy) and an alkyl halide to produce a mixture of two sulfonium diastereomers, usually in variable yields (Dalhoff et al., 2006a, 2006b; de la Haba, Jamieson, Mudd, & Richards, 1959; Stecher et al., 2009). The *S,S* diastereomer serves as the methyl donor, while the *S,R* diastereomer inhibits the methyltransferase (Borchardt & Wu, 1976; Khani-Oskouee, Jones, & Woodard, 1984). Additionally, analogs of SAM where sulfur is replaced with selenium are more reactive methyl donors due to the longer, weaker Se–C bonds and do not racemize (Iwig & Booker, 2004). Notably, select Se-adenosyl-L-selenomethionines (SeAM), i.e., propargyl SeAM, are more stable than their SAM analogs (Bothwell et al., 2012; Bothwell & Luo, 2014). Overall, these early synthetic efforts ignited investigations in which nonnatural SAM analogs could be used by endogenous methyltransferases to modify and profile various cellular targets.

To complement chemical synthesis of SAM analogs, we pioneered chemoenzymatic methods to expand the range of SAM analogs available for labeling methyltransferase substrates (Lipson et al., 2013; Thomsen et al., 2013; Vranken et al., 2016). We employed two homologous halogenases, SalL and FlA, to produce SAM and SAM analogs. As discussed earlier, SalL catalyzes the reaction of SAM with chloride to produce ClDA and L-methionine via nucleophilic attack in *S. tropica* (Fig. 1). Similarly, *S. cattleya* uses fluorinase FlA to react fluoride with SAM to afford FDA and L-methionine. Based on Le Chatelier's Principle, we hypothesized that

under low salt concentrations and excess L–methionine, these halogenases could catalyze the biologically reversed reaction to produce SAM in situ (Fig. 3) from easily prepared ClDA. Indeed, we observed SAM production by both SalL and FlA in various buffers, including Tris, HEPES, and phosphate buffers at pH 7–8, although SalL produced SAM in substantially higher yields than FlA. Furthermore, we generated a W190A point mutant of SalL that could accommodate larger alkyl substrates (Thomsen et al., 2013). Both wild type (WT) and mutant SalL generated alkyl, allylic, and benzylic SAM analogs, although the WT was most effective at generating small SAM analogs (methyl, ethyl), whereas both the WT and W190A mutant were equally effective at producing larger SAM analogs (propyl, butyl, allyl, and benzyl). Importantly, we demonstrated that our in situ-generated SAM congeners were recognized by nucleic acid, peptide, and small molecule methyltransferases and alkylated their respective substrates (Thomsen et al., 2013).

3.2 SalL-Mediated Chemoenzymatic Synthesis of SAM and SAM Analogs

3.2.1 Reagents

- DMSO (Sigma–Aldrich)
- HPLC grade acetonitrile (Fisher Scientific)
- 5′–chloro–5′–deoxyadenosine (Sigma–Aldrich)
- L–methionine (Sigma–Aldrich)
- S–ethyl–L–homocysteine (Sigma–Aldrich)
- S–propyl–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–butyl–L–homocysteine (Toronto Research Chemicals, Inc.)
- S–allyl–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–propargyl–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–benzyl–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–phenylethyl–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–(2–amino–2–carboxylethyl)–L–homocysteine (Sigma–Aldrich)
- S–(2–amino–2–oxoethyl)–L–homocysteine (prepared as described by Thomsen et al., 2013)
- S–adenosyl–L–methionine (New England Biolabs)

3.2.2 Enzyme
- SalL (expressed and purified as described in Section 2.1.2)

3.2.3 Stock Solutions and Buffers
- 300 mM ClDA in DMSO
- 150 mM L-methionine in 250 mM NaOH
- 15–150 mM L-methionine analog in 250 mM NaOH
- 32 mM SAM in 5 mM H$_2$SO$_4$ and 10% ethanol
- 50 mM sodium phosphate buffer, pH 6.8
- 400 mM sodium formate, pH 3.0
- 50 mM HEPES, pH 7.3

3.2.4 Analytical Instrumentation
- Agilent 6230 ESI-TOF LC-MS
- Agilent HPLC 1200
- Agilent Poroshell 300SB (5 μm, 2.1 × 75 mm) column

3.2.5 Procedure
1. Equilibrate 200 μM ClDA and 3 μM SalL in 50 mM phosphate buffer, pH 6.8 at 37°C.
2. Add 1.5–15 mM L-methionine or analog from stock. Due to the poor solubility of the benzyl and phenylethyl analogs of L–methionine, these were added at a final concentration of 1.5 mM from a 15 mM stock solution in 250 mM NaOH. L-Methionine and all other analogs were added at a final concentration of 15 mM from a 150 mM stock solution in 250 mM NaOH. In all assays, the addition of L-methionine or analog was 10% of the total reaction volume, resulting in a final pH of 7.4.
3. Quench reactions at various time points (0–5 h) by the addition of equal volumes of 400 mM sodium formate. Store quenched aliquots at 4°C until HPLC analysis.
4. Analyze aliquots using analytical reversed phase HPLC using a Synergi™ Hydro RP column (4 μm, 4.6 × 150 mm, Phenomenex) using the following gradient:
   Buffer A: 10 mM NH$_4$HCO$_2$, pH 3.2
   Buffer B: 90% CH$_3$CN, 10 mM NH$_4$HCO$_2$, pH 3.2
   0 min: 100% buffer A, 1 mL/min
   5 min: 98% buffer A, 1.5 mL/min
   10 min: 70% buffer A, 2 mL/min
   12 min: 0% buffer A, 2 mL/min

Table 1 LC-MS Retention Times and Chromatographic Analyses of Select SAM Analogs

Analog	Retention Time	Observed Monoisotopic Mass
SAM	4 min	399.1555
Ethyl–SAM	5 min	413.1671
Propyl–SAM	8.5, 8.9 min[a]	427.1784
Butyl–SAM	9.5 min	441.2366
Allyl–SAM	7.2, 7.9 min[a]	425.1862
Benzyl–SAM	10.4 min	475.2242

[a]Mixture of diastereomers.

> *Note*: Complete conversion of ClDA (retention time = 11 min) into SAM (retention time = 4 min) was observed within 30 min.

5. Verify the identity of ClDA and SAM by collecting 0.1 mL fractions from the HPLC and analyze by LC-MS. Table 1 provides a summary of LC-MS data for select SAM analogs. See Thomsen et al. (2013) for representative LC-MS traces and chromatograms.

3.3 In Situ Chemoenzymatic Synthesis of SAM Coupled to DNA Methylation by *Hha*I

*Hha*I is a DNA methyltransferase that methylates cytosine at C5 (Sankpal & Rao, 2002). In this assay, *Hha*I is coupled with in situ SAM production with methylation of lambda DNA.

3.3.1 Reagents
• N^6-methyladenine–free lambda DNA (New England Biolabs)

3.3.2 Enzymes
• SalL (expressed and purified as described in Section 2.1.2)
• *Hha*I methyltransferase (New England Biolabs)
• 0.2 U/μL HinP1I restriction enzyme (New England Biolabs)

3.3.3 Stock Solutions and Buffers
• 300 m*M* ClDA in DMSO
• 150 m*M* L-methionine in 250 m*M* NaOH
• *Hha*I buffer (5 m*M* 2-mercaptoethanol, 10 m*M* EDTA, 50 m*M* Tris–HCl, pH 7.5)

- NEB4 buffer (10 mM KOAc, 4 mM Tris–HOAc, 2 mM MgOAc$_2$, 0.2 mM dithiothreitol (DTT), pH 7.9)

3.3.4 Procedure

1. Equilibrate 50 ng/μL N^6-methyladenine-free lambda DNA, 4 U/μL *Hha*I, 200 μM ClDA, and 15 mM L-methionine in *Hha*I buffer at 37°C.

    Note: The buffers used for DNA methyltransferase *Hha*I and SalL activity assays were incompatible. *Hha*I was inactive in 50 mM sodium phosphate buffer, pH 7.9; however, the activity of SalL was reduced by 30% in *Hha*I buffer. Thus, coupled assays were conducted in *Hha*I buffer.

2. Add SalL to a final concentration of 900 nM.
3. After 1 h, quench reaction by heating at 80°C for 5 min.
4. Dilute reaction in an equal volume of HinP1I in 2× NEB4 buffer to afford a final concentration of 0.1 U/μL HinP1I.
5. Incubate 1 h at 37°C.
6. Analyze lambda DNA cleavage by gel electrophoresis on 2% agarose gel.

3.4 In Situ Chemoenzymatic Synthesis of SAM Coupled to Teicoplanin Methylation by MtfA

MtfA is a small molecule methyltransferase from the chloroeremomycin biosynthetic pathway in *Amycolatopsis orientalis* that catalyzes *N*-methylation of vancomycin–like glycopeptides (Shi et al., 2009). In this assay, MtfA is used to couple in situ SAM production with methylation of teicoplanin.

3.4.1 Reagents

- Teicoplanin (TargetMol)

3.4.2 Enzymes

- SalL (expressed and purified as described in Section 2.1.2)
- MtfA methyltransferase (expressed and purified as described below)

3.4.3 Stock Solutions and Buffers

- 300 mM ClDA in DMSO
- 150 mM L-methionine (or [*methyl*-^{13}C]-L-methionine) in 250 mM NaOH
- 50 mM HEPES, pH 7.3

3.4.4 Expression and Purification of MtfA Methyltransferase

One liter of $2\times$ YT medium (Sigma-Aldrich) supplemented with $50\,\mu g/mL$ kanamycin was inoculated with *E. coli* BL21 (DE3) cells transformed with *mtfA*/pET28a plasmid (obtained from Prof. Gerard D. Wright, McMaster University). The cells were cultured at 37°C to an OD_{600} of 0.6. The cells were cooled to 0°C on ice, induced with $100\,\mu M$ isopropyl β-D-1-thiogalactopyranoside (IPTG), and grown for 20 h at 16°C. Cells were harvested via centrifugation at $2000\times g$, 30 min, 4°C, and the pellet was resuspended in lysis buffer ($50\,mM$ HEPES, $500\,mM$ NaCl, $20\,mM$ imidazole, and $1\,mM$ DTT, pH 7.5) and lysed by passage through a French pressure cell. The lysate was clarified by centrifugation at $4150\times g$, 1.5 h, 4°C. His$_6$–MtfA was purified using 2 mL Ni–NTA resin (GE Healthcare) that was equilibrated with lysis buffer. The column was washed with 40 mL of buffer A ($50\,mM$ HEPES, 1 M NaCl, $20\,mM$ imidazole, $1\,mM$ DTT, pH 7.5), followed by 40 mL of buffer B ($50\,mM$ HEPES, $400\,mM$ NaCl, $30\,mM$ imidazole, $1\,mM$ DTT, pH 7.5). The protein was eluted with buffer C ($50\,mM$ HEPES, $400\,mM$ NaCl, $200\,mM$ imidazole, $1\,mM$ DTT, pH 7.5). We obtained around 50 mg of MtfA/L of cell culture. Eluted proteins were visualized with 12% SDS–PAGE with Coomassie Brilliant Blue staining. Imidazole was removed using spin concentration into $20\,mM$ HEPES, $20\,mM$ NaCl, and $5\,mM$ DTT, pH 7.5. Pure protein was stored at −20°C in $10\,mM$ HEPES, $10\,mM$ NaCl, $2.5\,mM$ DTT, pH 7.5 containing 50% glycerol. The protein is stable as a glycerol stock at −20°C.

3.4.5 Procedure

1. Equilibrate a $50\,\mu L$ mixture of $20\,mM$ ClDA, $50\,mM$ L–methionine, and $1.4\,\mu M$ SalL in $32\,mM$ phosphate buffer, pH 7.9 at 37°C.
2. After 1–3 h, add $250\,\mu L$ of a solution containing: $1\,mM$ teicoplanin, 1 mg/mL BSA, and $54\,\mu M$ MtfA in $50\,mM$ HEPES, pH 7.3.
3. Monitor the methylation of teicoplanin by removing aliquots at various times and analyzing by LC-MS using a C18 column ($3\,\mu m$, $2.1\times150\,mm$, Atlantis) and an isocratic mixture of 3:1 H_2O/CH_3CN (v/v) with 0.1% formic acid. Under these conditions, the retention times of teicoplanin and *N*–methyl–teicoplanin were 9 and 9.5 min, respectively.

3.5 In Situ Chemoenzymatic Synthesis of ^{13}C-Labeled SAM Coupled With Isotope Incorporation Into Teicoplanin via Methylation by MtfA

We envisioned SalL–mediated in situ chemoenzymatic synthesis of SAM as a compelling and facile way to incorporate isotopes into biomolecules. Here, we describe the use of this technology to incorporate ^{13}C into teicoplanin for sensitive NMR identification (Lipson et al., 2013).

3.5.1 Reagents
- d$_6$–DMSO (Cambridge Isotope Laboratories, Item No. DLM–10–10)
- [*Methyl*–^{13}C]–L–methionine (Cambridge Isotope Laboratories, Item No. CLM–206–PK)
- Teicoplanin (TargetMol)

3.5.2 Enzymes
- SalL (expressed and purified as described in Section 2.1.2)
- MtfA methyltransferase (expressed and purified as described in Section 3.4.4)

3.5.3 Stock Solutions and Buffers
- 300 mM ClDA in d$_6$–DMSO
- 300 mM [*methyl*–^{13}C]–L–methionine in d$_6$–DMSO
- 10 mM phosphate buffer, pH 7.5

3.5.4 Analytical Instrumentation
- Varian VX500 NMR spectrometer equipped with an X–Sens cold probe

3.5.5 Procedure
1. Prepare 800 μL of a mixture of 350 nM SalL and 350 nM MtfA in 10 mM phosphate buffer, pH 7.5.
2. Prepare 200 μL of a mixture of 7 mM teicoplanin, 142 mM [*methyl*–^{13}C]–L–methionine, and 14.2 mM ClDA in 10 mM phosphate buffer, pH 7.5 containing 50% d$_6$–DMSO.
3. Transfer the mixture of teicoplanin, [*methyl*–^{13}C]–L–methionine, and ClDA mixture to the mixture of SalL and MtfA.
4. Transfer the entire solution to a clean 5 mm NMR tube.

5. Collect ^{13}C-NMR spectra on a Varian VX500 NMR spectrometer at various time points. For each time point, we acquired data for ≥ 64 scans with a delay time (d1) of 5 s. In our hands, we observed the appearance of [methyl-^{13}C]-N-teicoplanin within 3–9 h, as evidenced by a ^{13}C-NMR signal at $\delta = 33.7$ ppm.

3.6 In Situ Chemoenzymatic Synthesis of SAM Coupled to RGG Peptide Methylation by rPRMT1

Protein arginine methyltransferase 1 (PRMT1) is responsible for the majority of arginine methylation in mammalian cells. In the assay described below, rPRMT1, a rat homolog that dimethylates arginine residues, is used to couple in situ SAM production with methylation of arginine residues in the RGG peptide. Transfer of ethyl, allyl, and benzyl congeners of L-methionine has also been observed (Thomsen et al., 2013). Overall, sterics likely influences transfer since we observed RGG allylation, but did not observe RGG propylation, although the corresponding SAM analogs have similar sizes and are formed in situ at similar rates. RGG allylation most likely occurs via an $S_N 2'$ mechanism.

3.6.1 Reagents
- RGG peptide (expressed and purified as described by Thomsen et al., 2013)

3.6.2 Enzymes
- SalL (expressed and purified as described in Section 2.1.2)
- rPRMT1 (expressed and purified as described by Thomsen et al., 2013)

3.6.3 Stock Solutions and Buffers
- 300 mM ClDA in DMSO
- 150 mM L-methionine in 250 mM NaOH
- 400 mM sodium formate, pH 3.0
- 50 mM phosphate buffer, pH 7.4

3.6.4 Procedure Peptide Methylation Using rPRMT1
1. Equilibrate a mixture containing 200 μM ClDA, 15 mM L-methionine, 1 μM SalL, 10 μM RGG peptide, and 2 μM rPRMT1 in 50 mM phosphate buffer, pH 7.4 at 37°C.
2. After 12 h, quench reaction by the addition of an equal volume of 400 mM sodium formate.
3. Assess the formation of methylated RGG peptide using LC-MS.

4. SUMMARY AND CONCLUSIONS

We described procedures for the chemoenzymatic synthesis of SAM and analogs that employ chlorinase SalL discovered from a marine actinomycete bacterium. Recombinant SalL can be purified from *E. coli* in relatively high yields, i.e., over 60 mg soluble enzyme per liter culture. The SalL-catalyzed synthesis of SAM analogs from L-methionine congeners and ClDA is diastereoselective. Moreover, we described methods for in situ synthesis of SAM coupled with DNA, protein, and metabolite methylation, and with the incorporation of isotopes into biomolecules.

In addition to SAM-dependent halogenases, numerous groups have used methionine adenosyltransferase wild type and mutants that accommodate structural changes in L-methionine and ATP to generate stable SAM analogs that alkylate a variety of acceptor substrates (Huber, Johnson, Zhang, & Thorson, 2016; Huber et al., 2016; Singh et al., 2014; Wang et al., 2013). Overall, the development of chemoenzymatic methods and protein engineering efforts has expanded the structural scope of SAM analogs that can be generated for biological studies.

REFERENCES

Agarwal, V., Miles, Z. D., Winter, J. M., Eustáquio, A. S., El Gamal, A. A., & Moore, B. S. (2017). Enzymatic halogenation and dehalogenation reactions: Pervasive and mechanistically diverse. *Chemical Reviews*, *117*, 5619–5674.

Bauerle, M. R., Schwalm, E. L., & Booker, S. J. (2015). Mechanistic diversity of radical S-adenosylmethionine (SAM)-dependent methylation. *Journal of Biological Chemistry*, *290*, 3995–4002.

Borchardt, R. T., & Wu, Y. S. (1976). Potential inhibitors of S-adenosylmethionine-dependent methyltransferases V: Role of the asymmetric

sulfonium pole in the enzymatic binding of S-adenosyl-ʟ-methionine. *Journal of Medicinal Chemistry*, *19*, 1099–1103.

Bothwell, I. R., Islam, K., Chen, Y., Zheng, W., Blum, G., Deng, H., et al. (2012). Se-adeonsyl-ʟ-selenomethionine cofactor analogue as a reporter of protein methylation. *Journal of the American Chemical Society*, *134*, 14905–14912.

Bothwell, I. R., & Luo, M. (2014). Large-scale, protection free synthesis of Se-adenosyl-ʟ-selenomethionine analogues and their application as cofactor surrogates of methyltransferases. *Organic Letters*, *16*, 3056–3059.

Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. *Analytical Biochemistry*, *72*, 248–254.

Cantoni, G. L. (1975). Biological methylation: Selected aspects. *Annual Review of Biochemistry*, *44*, 435–451.

Chan, K. K., & O'Hagan, D. (2012). The rare fluorinated natural products and biotechnological prospects for fluorine enzymology. *Methods in Enzymology*, *516*, 219–235.

Dalhoff, C., Lukinavicius, G., Klimasauskas, S., & Weinhold, E. (2006a). Direct transfer of extended groups from synthetic cofactors by DNA methyltransferases. *Nature Chemical Biology*, *2*, 31–32.

Dalhoff, C., Lukinavicius, G., Klimasauskas, S., & Weinhold, E. (2006b). Synthesis of S-adenosyl-ʟ-methionine analogs and their use for sequence-specific transalkylation of DNA by methyltransferases. *Nature Protocols*, *1*, 1879–1886.

de la Haba, G., Jamieson, G. A., Mudd, S. H., & Richards, H. H. (1959). S-adenosylmethionine: The relation of configuration at the sulfonium center to enzymatic reactivity. *Journal of the American Chemical Society*, *81*, 3975–3980.

Deng, H., Cobb, S. L., McEwan, A. R., McGlinchey, R. P., Naismith, J. H., O'Hagan, D., et al. (2006). The fluorinase from *Streptomyces cattleya* is also a chlorinase. *Angewandte Chemie*, *45*, 759–762.

Deng, H., Ma, L., Bandaranayaka, N., Qin, Z., Mann, G., Kyeremeh, K., et al. (2014). Identification of fluorinases from *Streptomyces* sp. MA37, *Norcardia brasiliensis*, and *Actinoplanes* sp. N902-109 by genome mining. *Chembiochem*, *15*, 364–368.

Dong, C., Huang, F., Deng, H., Schaffrath, C., Spencer, J. B., O'Hagan, D., et al. (2004). Crystal structure and mechanism of a bacterial fluorinating enzyme. *Nature*, *427*, 561–565.

Eustáquio, A. S., McGlinchey, R. P., Liu, Y., Hazzard, C., Beer, L. L., Florova, G., et al. (2009). Biosynthesis of the salinosporamide A polyketide synthase substrate chloroethylmalonyl-coenzyme A from S-adenosyl-ʟ-methionine. *Proceedings of the National Academy of Sciences of the United States of America*, *106*, 12295–12300.

Eustáquio, A. S., Pojer, F., Noel, J. P., & Moore, B. S. (2008). Discovery and characterization of a marine bacterial SAM-dependent chlorinase. *Nature Chemical Biology*, *4*, 66–74.

Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., & Fenical, W. (2003). Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus *Salinospora*. *Angewandte Chemie*, *42*, 355–357.

Fontecave, M., Atta, M., & Mulliez, E. (2004). S-adenosylmethionine: Nothing goes to waste. *Trends in Biochemical Sciences*, *29*, 243–249.

Gribble, G. W. (2012). Recently discovered naturally occurring heterocyclic organohalogen compounds. *Heterocycles*, *84*, 157–207.

Guo, H., Wang, R., Zheng, W., Chen, Y., Blum, G., Deng, H., et al. (2014). Profiling substrates of protein arginine N-methyltransferase 3 with S-adenosyl-ʟ-methionine analogues. *ACS Chemical Biology*, *9*, 476–484.

Hoffman, J. L. (1986). Chromatographic analysis of the chiral and covalent instability of S-adenosyl-ʟ-methionine. *Biochemistry*, *25*, 4444–4449.

Huang, S., Ma, L., Tong, M. H., Yu, Y., O'Hagan, D., & Deng, H. (2014). Fluoroacetate biosynthesis from the marine-derived bacterium *Streptomyces xinghaiensis* NRRL B-24674. *Organic and Biomolecular Chemistry*, *12*, 4828–4831.

Huber, T. D., Johnson, B. R., Zhang, J., & Thorson, J. S. (2016). AdoMet analog synthesis and utilization: Current state of the art. *Current Opinion in Biotechnology*, *42*, 189–197.

Huber, T. D., Wang, F., Singh, S., Johnson, B. R., Zhang, J., Sunkara, M., et al. (2016). Functional AdoMet isosteres resistant to classical AdoMet degradation pathways. *ACS Chemical Biology*, *11*, 2484–2491.

Islam, K., Bothwell, I., Chen, Y., Sengelaub, C., Wang, R., Deng, H., et al. (2012). Bioorthogonal profiling of protein methylation using azido derivative of *S*-adenosyl-L-methionine. *Journal of the American Chemical Society*, *134*, 5909–5915.

Islam, K., Chen, Y., Wu, H., Bothwell, I. R., Blum, G. J., Zeng, H., et al. (2013). Defining efficient enzyme-cofactor pairs for bioorthogonal profiling of protein methylation. *Proceedings of the National Academy of Sciences of the United States of America*, *110*, 16778–16783.

Islam, K., Zheng, W., Yu, H., Deng, H., & Luo, M. (2011). Expanding cofactor repertoire of protein lysine methyltransferase for substrate labeling. *ACS Chemical Biololgy*, *6*, 679–684.

Iwig, D. F., & Booker, S. J. (2004). Insight into the polar ractivity of the onium chalcogen analogues of *S*-adenosyl-L-methionine. *Biochemistry*, *43*, 13496–13509.

Jez, J. M., Ferrer, J. L., Bowman, M. E., Dixon, R. A., & Noel, J. P. (2000). Dissection of malonyl-coenzyme A decarboxylation from polyketide formation in the reaction mechanism of a plate polyketide synthase. *Biochemistry*, *39*, 890–902.

Khani-Oskouee, S., Jones, J. P., & Woodard, R. W. (1984). Stereochemical course of the biosynthesis of L-aminocyclopropane-1-carboxylic acid. I. Role of the asymmetric sulfonium pole and the α-amino acid center. *Biochemical and Biophysical Research Communications*, *121*, 181–187.

Lee, B. W., Sun, H. G., Zang, T., Kim, B. J., Alfaro, J. F., & Zhou, Z. S. (2010). Enzyme-catalyzed transfer of a ketone group from an *S*-adenosylmethionine analogue: A tool for the functional analysis of methyltransferases. *Journal of the American Chemical Society*, *132*, 3642–3643.

Lin, H. (2011). *S*-adenosylmethionine-dependent alkylation reactions: When are radical reactions used? *Bioorganic Chemistry*, *39*, 161–170.

Lipson, J. M., Thomsen, M., Moore, B. S., Clausen, R. P., La Clair, J. J., & Burkart, M. D. (2013). A tandem chemoenzymatic methylation of *S*-adenosyl-L-methionine. *Chembiochem*, *14*, 950–953.

Lukinavicius, G., Lapiene, V., Stasevskij, Z., Dalhoff, C., Weinhold, E., & Klimasauskas, S. (2007). Targeted labeling of DNA by methyltransferase-directed transfer of activated groups (mTAG). *Journal of the American Chemical Society*, *129*, 2758–2759.

Martin, J. L., & McMillan, F. M. (2002). SAM (dependent) I AM: The *S*-adenosylmethionine-dependent methyltransferase fold. *Current Opinion in Structural Biology*, *12*, 783–793.

Motorin, Y., Burhenne, J., Teimer, R., Koynov, K., Willnow, S., Weinhold, E., et al. (2011). Expanding the chemical scope of RNA: Methyltransferases to site-specific alkynylation of RNA for click labeling. *Nucleic Acids Research*, *39*, 1943–1952.

Ohashi, M., Liu, F., Hai, Y., Chen, M., Tang, M. C., Yang, Z., et al. (2017). SAM-dependent enzyme-catalysed pericyclic reactions in natural product biosynthesis. *Nature*, *549*, 502–506.

Peters, W., Willnow, S., Duisken, M., Kleine, H., Macherey, T., Duncan, K. E., et al. (2010). Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling. *Angewandte Chemie International Edition England*, *49*, 5170–5173.

Sankpal, U. T., & Rao, D. N. (2002). Structure, function, and mechanism of HhaI DNA methyltransferases. *Critical Reviews in Biochemistry and Molecular Biology*, *37*, 167–197.

Shi, R., Lamb, S. S., Zakeri, B., Proteau, A., Cui, Q., Sulean, T., et al. (2009). Structure and function of the glycopeptide *N*-methyltransferase MtfA, a tool for the biosynthesis of modified glycopeptide antibiotics. *Chemistry & Biology*, *16*, 401–410.

Singh, S., Zhang, J., Huber, T. D., Sunkara, M., Hurley, K., Goff, R. D., et al. (2014). Facile chemoenzymatic strategies for the synthesis and utilization of *S*-adenosyl-ʟ-methionine analogues. *Angewandte Chemie International Edition*, *53*, 3965–3969.

Sinhababu, A. K., Bartel, R. L., Pochopin, N., & Borchardt, R. T. (1985). Mechanism of action of *S*-adenosyl-ʟ-homocysteine hydrolase. Measurement of kinetic isotope effects using adenosine-3′-d and *S*-adenosyl-ʟ-homocysteine-3′-d as substrates. *Journal of American Chemical Society*, *107*, 7628–7632.

Stecher, H., Tengg, M., Ueberbacher, B. J., Remler, P., Schwab, H., Griengl, H., et al. (2009). Biocatalytic Friedel-Crafts alkylation using non-natural cofactors. *Angewandte Chemie International Edition England*, *48*, 9546–9548.

Struck, A. W., Thompson, M. L., Wong, L. S., & Micklefield, J. (2012). *S*-adenosyl-methionine-dependent methyltransferases: Highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. *Chembiochem*, *13*, 2642–2655.

Thomsen, M., Vogensen, S. B., Buchardt, J., Burkart, M. D., & Clausen, R. P. (2013). Chemoenzymatic synthesis and *in situ* application of *S*-adenosyl-ʟ-methionine analogs. *Organic and Biomolecular Chemistry*, *11*, 7606–7610.

Vranken, C., Fin, A., Tufar, P., Hofkens, J., Burkart, M. D., & Tor, Y. (2016). Chemoenzymatic synthesis and utilization of a SAM analog with an isomorphic nucleobase. *Organic and Biomolecular Chemistry*, *14*, 6189–6192.

Wang, R., Islam, K., Liu, Y., Zheng, W., Tang, H., Lailler, N., et al. (2013). Profiling genome-wide chromatin methylation with engineered posttranslation apparatus within living cells. *Journal of the American Chemical Society*, *135*, 1048–1056.

Wang, R., & Luo, M. (2013). A journey toward bioorthogonal profiling of protein methylation inside living cells. *Current Opinion in Chemical Biology*, *17*, 729–737.

Wang, R., Zheng, W., Yu, H., Deng, H., & Luo, M. (2011). Labeling substrates of protein arginine methyltransferase with engineered enzymes and matched *S*-adenosyl-ʟ-methionine analogues. *Journal of the American Chemical Society*, *133*, 7648–7651.

Wang, L., Zhou, X., Fredimoses, M., Liao, S., & Liu, Y. (2014). Naturally occurring organoiodines. *RSC Advances*, *4*, 57350–57376.

Winter, J. M., Chiou, G., Bothwell, I. R., Xu, W., Garg, N. K., Luo, M., et al. (2013). Expanding the structural diversity of polyketides by exploring the cofactor tolerance of an inline methyltransferase domain. *Organic Letters*, *15*, 3774–3777.

Zhang, C., Weller, R. L., Thorson, J. S., & Rajski, S. R. (2006). Natural product diversification using a non-natural cofactor analogue of *S*-adenosyl-ʟ-methionine. *Journal of the American Chemical Society*, *128*, 2760–2761.